Preferred Label : Anti-LAG-3/Anti-PD-L1 Bispecific Antibody IBI323;
NCIt synonyms : Anti-LAG-3/PD-L1 Bispecific Antibody IBI323; LAG-3 x PD-L1 Bispecific Antibody IBI323;
NCIt definition : A recombinant, bispecific antibody directed against two immune checkpoint proteins,
the inhibitory receptor lymphocyte activation gene 3 protein (LAG-3; LAG3) and the
immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation
274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities.
Upon administration, anti-LAG-3/anti-PD-L1 bispecific antibody IBI323 simultaneously
targets and binds to LAG-3 expressed on T-cells in the tumor microenvironment (TME)
and PD-L1 expressed on tumor cells. This prevents LAG-3- and PD-L1-mediated signaling,
reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte
(CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which
together lead to a reduction in tumor growth. LAG-3, a member of the immunoglobulin
superfamily (IgSF), negatively regulates both the proliferation and activation of
T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1
is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed
death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival
of CD8-positive T-cells, suppresses the immune system and results in immune evasion.;
Molecule name : IBI 323; IBI-323;
NCI Metathesaurus CUI : CL1663611;
Origin ID : C181022;
UMLS CUI : C5556787;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
